Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
NCT00984217 is a phase 2 interventional trial sponsored by University of Pittsburgh. As of 21 Nov 2026, it was withdrawn. It studies Panitumumab in Adenoma, Pleomorphic, Mixed Salivary Gland Tumor and 2 more conditions. The registry lists an enrollment of 0 participants at 27 sites in 1 country. The registry lists a start date of 31 Aug 2011 and a primary completion date of 31 Aug 2011.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00984217 |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of Pittsburgh |
| Enrollment | 0 |
| Registered sites | 27 |
| Countries | 1 |
| Conditions | Adenoma, Pleomorphic, Mixed Salivary Gland Tumor, Salivary Gland Tumor, Mixed and Syringoma, Chondroid |
| Drugs | Panitumumab |
| Start | 31 Aug 2011 |
| Primary completion | 31 Aug 2011 |
| Study completion | 31 Aug 2011 |
| Last update posted | 8 Jan 2016 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Michael K. Gibson, MD
University of Pittsburgh
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Upmc Cancer Center - Teramana Cancer Center - Steubenville
Steubenville
- Upmc Cancer Center - Beaver
Beaver
- Upmc Cancer Center - Clairton
Clairton
- Upmc Cancer Center - Arnold Palmer Pavilion - Greensburg
Greensburg
- Upmc Cancer Center - Oakbrook Commons
Greensburg
- Upmc Cancer Center - Oakbrook Commons - Greensburg
Greensburg
- Upmc Cancer Center -Arnold Palmer Pavilion
Greensburg
- Upmc Cancer Center - Indiana
Indiana
- Upmc Cancer Center - John P. Murtha Pavilion - Johnstown
Johnstown
- Upmc Cancer Center - Mckeesport
McKeesport
- Upmc Cancer Center - Monroeville
Monroeville
- Upmc Cancer Center - Sewickley Medical Oncology/hematology Group
Moon Township
- Upmc Cancer Center -Mt. Pleasant
Mount Pleasant
- Upmc Cancer Center - New Castle
New Castle
- Hillman Cancer Center: University of Pittsburgh Cancer Institute / Upmc Department of Radiology
Pittsburgh
- Upmc Cancer Center - Passavant
Pittsburgh
- Upmc Cancer Center - St. Margaret's
Pittsburgh
- Upmc Cancer Center - Upper St. Clair
Pittsburgh
- Upmc Cancer Center -Delafield Rd.
Pittsburgh
- Upmc Cancer Center -Drake
Pittsburgh
- Upmc Cancer Center -Upmc Shadyside
Pittsburgh
- Upmc Cancer Centers
Pittsburgh
- Upmc Presbyterian -Radiation Oncology
Pittsburgh
- Upmc Cancer Center -Upmc Northwest
Seneca
- Upmc Cancer Center - Uniontown
Uniontown
- Upmc Cancer Center - Washington
Washington
- Upmc Cancer Center - North Hills
Wexford
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00984217
Each answer restates registry values shown on this page.
What is NCT00984217?
NCT00984217 is a phase 2 interventional trial sponsored by University of Pittsburgh. It studies Panitumumab in Adenoma, Pleomorphic, Mixed Salivary Gland Tumor and 2 more conditions.
Who leads NCT00984217?
The registry names Michael K. Gibson, MD (principal investigator, University of Pittsburgh) as the overall official.
Where does NCT00984217 run?
The registry lists 27 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00984217 study?
The registered drug and biological interventions are Panitumumab.
When did NCT00984217 end?
The registry lists a primary completion date of 31 Aug 2011 and a study completion date of 31 Aug 2011. The sponsor last updated the record on 8 Jan 2016.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.